deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
abiraterone plus ADT vs. androgen deprivation therapy (ADT) 2 0.63
apalutamide plus ADT vs. androgen deprivation therapy (ADT) 1 0.67
docetaxel plus ADT vs. androgen deprivation therapy (ADT) 4 0.76
enzalutamide plus ADT vs. androgen deprivation therapy (ADT) 2 0.66
versus docetaxel plus ADT
abiraterone plus docetaxel plus ADT vs. docetaxel plus ADT 1 0.75
darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT 1 0.68